Incidence of CNS metastases as first site of relapse was @ % ( eight of @ patients ) for lapatinib-capecitabine and @ % ( @ of @ patients ) for trastuzumab-capecitabine ( treatment differences , -@ % ; @ % CI , -@ % to @ % ; P = @ ) .